shape therapeutics leadership team

Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. All rights reserved. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. April 20, 2021 08:00 ET SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . Claim your profile to get in front of buyers, investors, and analysts. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Im thrilled to join such a talented team of innovative thinkers. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . | Source: You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . About. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. This is a profile preview from the PitchBook Platform. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Shape Life! Discover current leadership team members including founders, CEO, other executives and board directors. Shape Therapeutics, Inc. They seem respectful towards one another. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. 2023 PitchBook. A free inside look at company reviews and salaries posted anonymously by employees. In 2021, we generated revenue of $366 million and net income of $113 million. 69% of the management team is White. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). As Doug noted, our full year net product revenue was $843.8 million . I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. You can read more about your cookie choices at our privacy policyhere. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Shape Therapeutics, Inc. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Shape Therapeutics is . Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, [email protected]. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Learn more. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Boston, MA 02111. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. . Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Interested in researching Shape Therapeutics? We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Sign up for a free account. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Glad that you want to get updates from Shape Therapeutics. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 We have this culture of innovating. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. A free inside look at company reviews and salaries posted anonymously by employees. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. resistance to cancer treatment. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, [email protected], Media Contact:IDLydia [email protected]. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Shape Therapeutics's is . ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". People. Our Story. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Powered by Madgex Job Board Software. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. No credit card required. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Copyright 2023 CB Information Services, Inc. All rights reserved. We have to be creative; we need to transform the paradigm. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Our Commitment to Diversity. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. our sites and services. Do you excel more in a team or individual setting? Operating Status Active. Headquarters Location 219 Terry Ave N Suite 100 Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. [email protected], 1985 - 2023 BioSpace.com. Get the full list, Youre viewing 5 of 9 board members. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). million verified professionals across 35 million companies. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. ", I feel this real connection to the patients were having an impact on. What is health insurance like at Shape Therapeutics? With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Operator. 219 Terry Avenue North Shape Therapeutics, Inc. employs 14 employees. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Chief Operating Officer. I cannot imagine being anyplace else.". Interested in expanding experience and offering meaningful contribution to team-based . I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. All rights reserved. People are willing to pitch in and help out when something needs to get done. Contact Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. CBI websites generally use certain cookies to enable better interactions with. Type Private Status Active Founded 2018 HQ By continuing to use this site you are consenting to these choices. focus on diversity and equityRead More. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Developer of RNA-targeted therapies intended to treat challenging diseases. from Harvard Law School. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. 11 Shape Therapeutics reviews. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. You can find us at shapetx.com and on LinkedIn and Twitter. And I don't just mean the science but also on healthcare policy. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. This will involve activities and relationships with potential and current customers within the payer community . Interested in what they do or partnership? it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Founded Date Apr 5, 2018. . Explore {Shape Therapeutics's key management people. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Meet members of our executive team at StrideBio. July 15, 2021 08:00 ET At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Founders Francois Vigneault, John Suliman, Prashant Mali. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Chief Scientific Officer, Francois Vigneault Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). You can read more about your. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Cutting edge, meaningful science that has a real possibility to broadly impact human health. Chief Business Officer, Will Krause We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. ", Im here to bring genetic medicine to life. Get started with your Free Employer Profile, Work Here? The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. John C. Martin, Ph.D., was elected to our Board in January 2020. Shape Life! I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. free lookups / month. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. And I thought, imagine how Ill feel if we can reach more kids. 56% of the management team is White. Shape Life! Investors & Media The net loss for the full . Enter employee name to find & verify emails, phones, social links, etc. We have plenty of data and we can help. The company closed a series B financing led by . The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Its very rewarding. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. See what employees say it's like to work at Shape Therapeutics. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Lorem ipsum dolor sit, amet consectetur adipisicing elit. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. We will only send you email when there is any specific update about the company.

Saugus Advertiser Police Log, Flipping Oyster Cages, Articles S